Merck and Ridgeback's oral antiviral investigational drug molnupiravir reduced the risk of hospitalization or death compared to placebo in patients with mild or moderate Covid-19 by about 50 percent in a positive interim analysis of the phase 3 study. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared- to-placebo-for-patients-with-mild-or-moderate /. Published October 1, 2021. Accessed October 1, 2021.

© Copyright 2024, All Rights Reserved  |